3′-[18F]fluoro-3′-deoxythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease

Cancer Research

Volumn 63, Issue 10, 2003, Pages 2681-2687

  Wagner, Martin ^a   Seitz, Ulrike ^a   Buck, Andreas ^a   Neumaier, Bernd ^a   Schultheiß, Stefan ^a   Bangerter, Markus ^a   Bommer, Martin ^a   Leithäuser, Frank ^a   Wawra, Edgar ^b   Munzert, Gerd ^a   Reske, Sven N ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE; 3' FLUOROTHYMIDINE F 18; FLUORODEOXYGLUCOSE F 18; KI 67 ANTIGEN; PERCHLORIC ACID; THYMIDINE KINASE; THYMIDINE KINASE 1; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; DIAGNOSTIC AGENT; FLUORINE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; B CELL LYMPHOMA; CANCER DIAGNOSIS; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INCUBATION TIME; ISOTOPE LABELING; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIOACTIVITY; RELIABILITY; ANIMAL; CANCER TRANSPLANTATION; CELL CULTURE; CELL DIVISION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE MODEL; METABOLISM; MOUSE; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION; XENOGRAFT;

ANIMALS; CELL DIVISION; DIDEOXYNUCLEOSIDES; DISEASE MODELS, ANIMAL; FLUORINE RADIOISOTOPES; HUMANS; LYMPHOMA, B-CELL; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; PILOT PROJECTS; RADIOPHARMACEUTICALS; THYMIDINE KINASE; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0038179858     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Goldberg, M. A., Lee, M. J., Fischman, A. J., Mueller, P. R., Alpert, N. M., and Thrall, J. H. Fluorodeoxyglucose PET of abdominal and pelvic neoplasms: potential role in oncologic imaging. Radiographics, 13: 1047-1062, 1993.
2. Higashi, T., Tamaki, N., Honda, T., Torizuka, T., Kimura, T., Inokuma, T., Ohshio, G., Hosotani, R., Imamura, M., and Konishi, J. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study. J. Nucl. Med., 38: 1337-1344, 1997.
3. Reske, S. N., Grillenberger, K. G., Glatting, G., Port, M., Hildebrandt, M., Gansauge, F., and Beger, H. G. Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J. Nucl. Med., 38: 1344-1348, 1997.
4. Bangerter, M., Moog, F., Buchmann, I., Kotzerke, J., Griesshammer, M., Hafner, M., Elsner, K., Frickhofen, N., Reske, S. N., and Bergmann, L. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease. Ann. Oncol., 9: 1117-1122, 1998.
5. Carr, R., Barrington, S. F., Madan, B., O'Doherty, M. J., Saunders, C. A., van der Walt, J., and Timothy, A. R. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood, 91: 3340-3346, 1998.
6. Moog, F., Bangerter, M., Diederichs, C. G., Guhlmann, A., Kotzerke, J., Merkle, E., Kolokythas, O., Herrmann, F., and Reske, S. N. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology, 203: 795-800, 1997.
7. Moog, F., Bangerter, M., Diederichs, C. G., Guhlmann, A., Merkle, E., Frickhofen, N., and Reske, S. N. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology, 206: 475-481, 1998.
8. Moog, F., Bangerter, M., Kotzerke, J., Guhlmann, A., Frickhofen, N., and Reske, S. N. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J. Clin. Oncol., 16: 603-609, 1998.
9. Jerusalem, G., Beguin, Y., Fassotte, M. F., Najjar, F., Paulus, P., Rigo, P., and Fillet, G. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood, 94: 429-433, 1999.
10. Lapela, M., Leskinen, S., Minn, H. R., Lindholm, P., Klemi, P. J., Soderstrom, K. O., Bergman, J., Haaparanta, M., Ruotsalainen, U., Solin, O., et al. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood, 86: 3522-3527, 1995.
11. Martial, P., Ferrant, A., Labar, D., Cogneau, M., Bol, A., Michel, C., Michaux, J. L., and Sokal, G. In vivo measurement of carbon-II thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. J. Nucl. Med., 29: 1633-1637, 1988.
12. 11C]thymidine PET imaging studies: validation studies. J. Nucl. Med., 40: 614-624, 1999.
13. Seitz, U., Wagner, M., Vogg, A. T., Glatting, G., Neumaier, B., Greten, F. R., Schmid, R. M., and Reske, S. N. In vivo evaluation of 5-[(18)F]fluoro-2′-deoxyuridine as tracer for positron emission tomography in a murine pancreatic cancer model. Cancer Res., 61: 3853-3857, 2001.
14. Shields, A. F., Grierson, J. R., Dohmen, B. M., Machulla, H. J., Stayanoff, J. C., Lawhorn-Crews, J. M., Obradovich, J. E., Muzik, O., and Mangner, T. J. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat. Med., 4: 1334-1336, 1998.
15. Buck, A. K., Schirrmeister, H., Hetzel, M., Von Der Heide, M., Halter, G., Glatting, G., Mattfeldt, T., Liewald, F., Reske, S. N., and Neumaier, B. 3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res., 62: 3331-3334, 2002.
16. Rasey, J. S., Grierson, J. R., Wiens, L. W., Kolb, P. D., and Schwartz, J. L. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J. Nucl. Med., 43: 1210-1217, 2002.
17. Kong, X. B., Zhu, Q. Y., Vidal, P. M., Watanabe, K. A., Polsky, B., Armstrong, D., Ostrander, M., Lang, S. A., Jr., Muchmore, E., and Chou, T. C. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob. Agents Chemother., 36: 808-818, 1992.
18. Belt, J. A., Marina, N. M., Phelps, D. A., and Crawford, C. R. Nucleoside transport in normal and neoplastic cells. Adv. Enzyme Regul., 33: 235-252, 1993.
19. Mackey, J. R., Mani, R. S., Selner, M., Mowles, D., Young, J. D., Belt, J. A., Crawford, C. R., and Cass, C. E. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res., 58: 4349-4357, 1998.
20. Mier, W., Haberkorn, U., and Eisenhut, M. [18F]FLT: portrait of a proliferation marker. Eur. J. Nucl. Med. Mol. Imaging. 29: 165-169, 2002.
21. Sherley, J. L., and Kelly, T. J. Regulation of human thymidine kinase during the cell cycle. J. Biol. Chem., 263: 8350-8358, 1988.
22. Sakamoto, S., Ebuchi, M., and Iwama, T. Relative activities of thymidylate synthetase and thymidine kinase in human mammary tumours. Anticancer Res., 13: 205-207, 1993.
23. Romain, S., Martin, P. M., Klijn, J. G., van Putten, W. L., Look, M. P., Guirou, O., and Foekens, J. A. DNA-synthesis enzyme activity: a biological tool useful for predicting anti-metabolic drug sensitivity in breast cancer? Int. J. Cancer, 74: 156-161, 1997.
24. Kluin-Nelemans, H. C., Limpens, J., Meerabux, J., Beverstock, G. C., Jansen, J. H., de Jong, D., and Kluin, P. M. A new non-Hodgkin's B-cell line (DoHH2) with a chromosomal translocation t(14:18)(q32;q21). Leukemia, 5: 221-224, 1991.
25. de Kroon, J. F., Kluin, P. M., Kluin-Nelemans, H. C., Willemze, R., and Falkenburg, J. H. Homing and antigenic characterization of a human non-Hodgkin's lymphoma B cell line in severe combined immunodeficient (SCID) mice. Leukemia. 8: 1385-1391, 1994.
26. Cotter, F. E., Johnson, P., Hall, P., Pocock, C., al Mahdi, N., Cowell, J. K., and Morgan, G. Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene, 9: 3049-3055, 1994.
27. Seitz, U., Wagner, M., Neumaier, B., Wawra, E., Glatting, G., Leder, G., Schmid, R. M., and Reske, S. N. Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3′-[(18)F]fluoro-3′-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines. Eur. J. Nucl. Med. Mol. Imaging, 29: 1174-1181, 2002.
28. Siegmund, H., and Pfleiderer, W. The synthesis of phospholipid conjugates of antivirally active nucleosides by the improved phosphoramidite methodology. Helv. Chim. Acta. 79: 426-438, 1996.H. P.
29. Machulla, H. J., Blocher, A., Kuntzsch, M., Piert, M., Wei, R., Grierson, J. R. Simplified Labeling Approach for Synthesizing 3′-Deoxy-3′-[18F]Fluorothymidine ([18F]FLT). J. Rad. Nucl. Chem., 243: 843-846, 2000.
30. Richards, G. M. Modifications of the diphenylamine reaction giving increased sensitivity and simplicity in the estimation of DNA. Anal. Biochem., 57: 369-376, 1974.
31. Voit, C., Mayer, T., Proebstle, T. M., Weber, L., Kron, M., Krupienski, M., Zeelen, U., Sterry, W., and Schoengen, A. Ultrasound-guided fine-needle aspiration cytology in the early detection of melanoma metastases. Cancer, 90: 186-193, 2000.
32. Eriksson, S., Arner, E., Spasokoukotskaja, T., Wang, L., Karlsson, A., Brosjo, O., Gunven, P., Julusson, G., and Liliemark, J. Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy. Adv. Enzyme Regul., 34: 13-25, 1994.
33. Clavo, A. C., Brown, R. S., and Wahl, R. L. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J. Nucl. Med., 36: 1625-1632, 1995.
34. Kubota, R., Kubota, K., Yamada, S., Tada, M., Ido, T., and Tamahashi, N. Microautoradiographic study for the differentiation of intratumoral macrophages, granulation tissues and cancer cells by the dynamics of fluorine-18-fluorodeoxyglucose uptake. J. Nucl. Med., 35: 104-112, 1994.
35. Haberkorn, U., Ziegler, S. I., Oberdorfer, F., Trojan, H., Haag, D., Peschke, P., Berger, M. R., Altmann, A., and van Kaick, G. FDG uptake, tumor proliferation and expression of glycolysis associated genes in animal tumor models. Nucl. Med. Biol., 21: 827-834, 1994.
36. Ito, M., and Conrad, S. E. Independent regulation of thymidine kinase mRNA and enzyme levels in serum-stimulated cells. J. Biol. Chem., 265: 6954-6960, 1990.
37. Arner, E. S., and Eriksson, S. Mammalian deoxyribonucleoside kinases. Pharmacol. Ther., 67: 155-186, 1995.
38. Kristensen, T., Jensen, H. K., and Munch-Petersen, B. Overexpression of human thymidine kinase mRNA without corresponding enzymatic activity in patients with chronic lymphatic leukemia. Leuk. Res., 18: 861-866, 1994.
39. Plagemann, P. G. W., and Wohlhueter, R. M. Permeation of nucleosides, nucleic acid bases, and nucleotides in animal cells. In: F. Bronner and A. Kleinzeller (eds.), Current Topics in Membranes and Transport XIV, pp. 225-330. New York: Academic Press, 1980.
40. Sundseth, R., Joyner, S. S., Moore, J. T., Dornsife, R. E., and Dev, I. K. The anti-human immunodeficiency virus agent 3′-fluorothymidine induces DNA damage and apoptosis in human lymphoblastoid cells. Antimicrob. Agents Chemother. 40: 331-335, 1996.
41. Balzarini, J., Baba, M., Pauwels, R., Herdewijn, P., and De Clerq, E. Anti-retrovirus activity of 3′-fluoro- and 3′-azido-substituted pyrimidine 2′,3′-dideoxynucleoside analogues. Biochem. Pharmacol., 37: 2847-2856, 1988.